Insilico Medicine completes first-in-patient dosing of ISM3412, the novel MAT2A inhibitor for the treatment of locally advanced/metastatic solid tumors - EurekAlert!
Insilico Medicine receives IND approval from FDA for novel MAT2A inhibitor ISM3412 - EurekAlert
